A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractory PTCL, exhibiting response rates of 25% and 29% respe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Amengual, Jennifer E., Lichtenstein, Renee, Lue, Jennifer, Sawas, Ahmed, Deng, Changchun, Lichtenstein, Emily, Khan, Karen, Atkins, Laine, Rada, Aishling, Kim, Hye A., Chiuzan, Codruta, Kalac, Matko, Marchi, Enrica, Falchi, Lorenzo, Francescone, Mark A., Schwartz, Lawrence, Cremers, Serge, O’Connor, Owen A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5790128/
https://ncbi.nlm.nih.gov/pubmed/29141948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-806737
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados